Last reviewed · How we verify
Anti-hypertensive Agents
Anti-hypertensive agents lower blood pressure through various mechanisms including vasodilation, reduced cardiac output, or decreased peripheral vascular resistance.
Anti-hypertensive agents lower blood pressure through various mechanisms including vasodilation, reduced cardiac output, or decreased peripheral vascular resistance. Used for Hypertension (essential and secondary), Hypertensive emergency, Prevention of cardiovascular events in hypertensive patients.
At a glance
| Generic name | Anti-hypertensive Agents |
|---|---|
| Also known as | benazepril (Lotensin, Zestril, Altace), chlorthalidone (Thalitone), metoprolol (Toprol XL), diltiazem (Tiazac), plendil (Felodipine) |
| Sponsor | National Heart, Lung, and Blood Institute (NHLBI) |
| Drug class | Anti-hypertensive agents (multiple classes: ACE inhibitors, ARBs, beta-blockers, calcium channel blockers, diuretics, etc.) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Anti-hypertensive agents represent a broad class of drugs used to treat hypertension by targeting different physiological pathways. Common mechanisms include ACE inhibition, angiotensin II receptor blockade, beta-adrenergic blockade, calcium channel antagonism, and diuresis. These drugs work individually or in combination to reduce blood pressure and prevent cardiovascular complications.
Approved indications
- Hypertension (essential and secondary)
- Hypertensive emergency
- Prevention of cardiovascular events in hypertensive patients
Common side effects
- Hypotension
- Dizziness
- Fatigue
- Headache
- Cough (ACE inhibitors)
- Hyperkalemia (ACE inhibitors/ARBs)
- Edema (calcium channel blockers)
Key clinical trials
- Effect of Hypertensive Drugs on Root Caries Among Senior Patients in Cairo University
- CENtral Blood Pressure Targeting: A Pragmatic RAndomized Pilot triaL in Advanced Chronic Kidney Disease (NA)
- The GUARDIAN Pilot Trial (NA)
- Focusing on the Menopausal Transition to Improve Mid-Life Women's Health (PHASE2, PHASE3)
- Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control (NA)
- PHASE III, RANDOMIZED, ACTIVE-COMPARATOR CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF NIFEDIPINE 30MG EXTENDED-RELEASE IN ADULT PATIENTS DIAGNOSED WITH MILD OR MODERATE HYPERTENSION IN COLOMBIA. (PHASE3)
- Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance (PHASE4)
- SPYRAL GEMINI Pilot Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |